BE2013C036I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C036I2
BE2013C036I2 BE2013C036C BE2013C036C BE2013C036I2 BE 2013C036 I2 BE2013C036 I2 BE 2013C036I2 BE 2013C036 C BE2013C036 C BE 2013C036C BE 2013C036 C BE2013C036 C BE 2013C036C BE 2013C036 I2 BE2013C036 I2 BE 2013C036I2
Authority
BE
Belgium
Application number
BE2013C036C
Other languages
French (fr)
Original Assignee
Sanofi Mature Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Mature Ip filed Critical Sanofi Mature Ip
Publication of BE2013C036I2 publication Critical patent/BE2013C036I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2013C036C 2003-09-19 2013-06-13 BE2013C036I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (en) 2003-09-19 2003-09-19 ACETONIC SOLVAT OF DIMETHOXY DOCETAXEL AND PROCESS FOR PREPARING THE SAME
PCT/FR2004/002344 WO2005028462A1 (en) 2003-09-19 2004-09-16 Dimethoxy docetaxel acetone solvate et method for the preparation thereof

Publications (1)

Publication Number Publication Date
BE2013C036I2 true BE2013C036I2 (en) 2023-12-14

Family

ID=34224354

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C036C BE2013C036I2 (en) 2003-09-19 2013-06-13

Country Status (37)

Country Link
US (1) US7241907B2 (en)
EP (1) EP1667986B1 (en)
JP (1) JP5010279B2 (en)
KR (1) KR101123588B1 (en)
CN (1) CN100429207C (en)
AR (1) AR045667A1 (en)
AU (1) AU2004274212B2 (en)
BE (1) BE2013C036I2 (en)
BR (1) BRPI0414492A8 (en)
CA (1) CA2539309A1 (en)
CR (1) CR8292A (en)
CY (2) CY1114575T1 (en)
DK (1) DK1667986T3 (en)
ES (1) ES2403149T4 (en)
FR (2) FR2859996B1 (en)
HR (1) HRP20130322T1 (en)
HU (1) HUS1300025I1 (en)
IL (1) IL174240A (en)
LU (1) LU92172I2 (en)
MA (1) MA28045A1 (en)
ME (2) ME00054B (en)
MX (1) MXPA06002639A (en)
MY (1) MY136668A (en)
NO (2) NO335997B1 (en)
NZ (1) NZ545835A (en)
PA (1) PA8612401A1 (en)
PE (1) PE20050870A1 (en)
PL (1) PL1667986T3 (en)
PT (1) PT1667986E (en)
RS (2) RS54614B1 (en)
RU (1) RU2342373C2 (en)
SI (1) SI1667986T1 (en)
TN (1) TNSN06086A1 (en)
TW (1) TWI382022B (en)
UA (1) UA87115C2 (en)
WO (1) WO2005028462A1 (en)
ZA (1) ZA200602255B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533330A (en) * 2006-03-21 2009-09-17 ドクター レディズ ラボラトリーズ リミテッド Docetaxel polymorphs and processes
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
FR2926551A1 (en) * 2008-01-17 2009-07-24 Aventis Pharma Sa CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME
JP5588983B2 (en) 2008-08-11 2014-09-10 ウェルズ ファーゴ バンク ナショナル アソシエイション Multi-arm polymer alkanoate conjugate
FR2945211A1 (en) 2009-05-06 2010-11-12 Sanofi Aventis ANTITUMOR COMBINATION COMPRISING CABAZITAXEL AND CAPECITABINE
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
KR101712231B1 (en) * 2009-10-29 2017-03-03 아벤티스 파마 소시에떼아노님 Novel antitumoral use of cabazitaxel
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012142117A1 (en) 2011-04-12 2012-10-18 Plus Chemicals Sa Solid state forms of cabazitaxel and processes for preparation thereof
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (en) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 Crystalline forms of cabazitaxel
CN103906747A (en) 2011-10-31 2014-07-02 台湾神隆股份有限公司 Preparation method of cabazitaxel and its intermediate
WO2013065070A1 (en) 2011-11-01 2013-05-10 Fresenius Kabi Encology Ltd. Amorphous form of cabazitaxel and process for its preparation
ES2716799T3 (en) * 2011-11-28 2019-06-17 Fresenius Kabi Oncology Ltd Crystal form of cabazitaxel and process for the preparation of it
EP2791122B1 (en) 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
US9403785B2 (en) 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
JP2015509929A (en) * 2012-02-10 2015-04-02 アベンティス・ファーマ・ソシエテ・アノニム Use of cabazitaxel for new children
US9394266B2 (en) 2012-03-08 2016-07-19 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (en) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 Cabazitaxel crystal and preparation method thereof
CN102746258B (en) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 Crystal forms of cabazitaxel and preparation method thereof
EP2880021A4 (en) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd Amorphous cabazitaxel
EP2884963B1 (en) 2012-08-15 2017-12-27 Yung Shin Pharm. Ind. Co. Ltd. Stable pharmaceutical formulation of cabazitaxel
CN103664836B (en) * 2012-09-20 2016-04-20 齐鲁制药有限公司 Crystal form A of 7 β, 10 β-dimethoxy docetaxel deuterated acetone compound and preparation method thereof
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (en) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 Jevtana solvate and preparation method and application thereof
CN103058960B (en) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 Cabazitaxel polymorphic form and preparation method thereof
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910696B (en) * 2012-12-30 2016-01-20 上海医药工业研究院 Cabazitaxel isopropyl ether compound and crystallization thereof
CN103910698B (en) * 2012-12-30 2016-01-20 上海医药工业研究院 Cabazitaxel acetone compound and crystallization thereof
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015000165A1 (en) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 Stable transformation product of dimethoxy docetaxel mono-acetonate and crystalline forms thereof, and methods for preparation of same
CN104277014A (en) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 Stable conversion products of dimethoxy docetaxel monoacetonide, and crystallization forms and preparation method thereof
EP2865675A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN103601704B (en) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 Preparation method of amorphous cabazitaxel
WO2016113752A2 (en) 2015-01-12 2016-07-21 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
JP6841772B2 (en) * 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
EP3548497A4 (en) 2016-11-29 2020-09-02 Censa Pharmaceuticals Inc. POLYMORPHES OF SEPIAPTERIN AND SALT THEREOF
CN110312721A (en) 2016-11-29 2019-10-08 显莎制药公司 The polymorph of sepiapterin
EP3675863A4 (en) 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. PHARMACEUTICAL COMPOSITION CONSISTING OF SEPIAPTERIN AND ITS USES
BR112020024329A2 (en) 2018-05-30 2021-02-23 Ptc Therapeutics Mp, Inc. compositions and methods for increasing plasma exposure of tetrahydrobiopterin
MD3801536T2 (en) 2018-05-30 2024-11-30 Ptc Therapeutics Mp Inc Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
FR2722191B1 (en) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF (2R, 3S) -3-TERTBUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE (2R, 3S) TRIHYDRATE, 20EPOXY-11BYA -13ALPHA-YLE
DE4425978C1 (en) * 1994-07-22 1995-11-23 Karlsruhe Forschzent Microstructured ceramic body prodn.
MA23823A1 (en) * 1995-03-27 1996-10-01 Aventis Pharma Sa NEW TAXOIDS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
FR2745814B1 (en) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2771092B1 (en) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF DERIVATIVES OF THE TAXOID CLASS
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
JP2002544269A (en) * 1999-05-17 2002-12-24 ブリストル−マイヤーズ スクイブ カンパニー New reaction conditions for the cleavage of silyl ethers in the production of paclitaxel and paclitaxel analogs
RU2284328C2 (en) * 2001-11-29 2006-09-27 Дайити Фармасьютикал Ко., Лтд. Crystals of taxane derivatives and method for their preparing

Also Published As

Publication number Publication date
KR20060072147A (en) 2006-06-27
PT1667986E (en) 2013-04-24
IL174240A0 (en) 2006-08-01
CY1114575T1 (en) 2016-10-05
MA28045A1 (en) 2006-07-03
CA2539309A1 (en) 2005-03-31
AU2004274212A1 (en) 2005-03-31
CR8292A (en) 2008-10-15
MXPA06002639A (en) 2006-06-05
RS20060189A (en) 2008-06-05
NO2015013I1 (en) 2015-05-04
RU2006113122A (en) 2006-08-27
ES2403149T3 (en) 2013-05-14
PA8612401A1 (en) 2005-08-04
HK1093340A1 (en) 2007-03-02
LU92172I2 (en) 2013-05-21
NZ545835A (en) 2009-10-30
ME00054B (en) 2011-02-10
MY136668A (en) 2008-11-28
US20050065138A1 (en) 2005-03-24
CN1849311A (en) 2006-10-18
AR045667A1 (en) 2005-11-02
DK1667986T3 (en) 2013-05-06
JP5010279B2 (en) 2012-08-29
NO20061714L (en) 2006-04-19
CY2013016I1 (en) 2018-01-10
AU2004274212B2 (en) 2010-03-04
BRPI0414492A8 (en) 2019-01-15
PE20050870A1 (en) 2005-11-21
RS54614B1 (en) 2016-08-31
TNSN06086A1 (en) 2007-10-03
MEP11708A (en) 2010-06-10
JP2007505866A (en) 2007-03-15
EP1667986B1 (en) 2013-01-16
PL1667986T3 (en) 2013-06-28
FR2859996B1 (en) 2006-02-03
BRPI0414492A (en) 2006-11-14
CY2013016I2 (en) 2018-01-10
HUS1300025I1 (en) 2016-08-29
HRP20130322T1 (en) 2013-07-31
SI1667986T1 (en) 2013-05-31
NO2015013I2 (en) 2015-04-22
FR13C0037I2 (en) 2015-11-20
TWI382022B (en) 2013-01-11
TW200524891A (en) 2005-08-01
ES2403149T4 (en) 2013-06-24
FR13C0037I1 (en) 2013-09-08
EP1667986A1 (en) 2006-06-14
ZA200602255B (en) 2007-07-25
KR101123588B1 (en) 2012-03-22
RU2342373C2 (en) 2008-12-27
UA87115C2 (en) 2009-06-25
WO2005028462A1 (en) 2005-03-31
US7241907B2 (en) 2007-07-10
NO335997B1 (en) 2015-04-20
LU92172I9 (en) 2019-01-03
CN100429207C (en) 2008-10-29
IL174240A (en) 2010-12-30
FR2859996A1 (en) 2005-03-25

Similar Documents

Publication Publication Date Title
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
JP2004096725A5 (en)
BE2013C034I2 (en)
BE2012C053I2 (en)
AU2002327736A1 (en)
AU2002339901A1 (en)
AU2002249912A1 (en)
AU2002253451A1 (en)
AU2002254171A1 (en)
AU2002255066A1 (en)
AU2002256398A1 (en)
AU2002310561A1 (en)
AU2002311957A1 (en)
AU2002316235A1 (en)
AU2002316511A1 (en)
AU2002318342A1 (en)
AU2002321535A1 (en)
AU2002322913A1 (en)
AU2002324323A1 (en)
AU2002327042A1 (en)
AU2002245368A1 (en)
AU2002331433A1 (en)
AU2002332887A1 (en)